Warning: file_get_contents(https://multipass.sense-studios.com/check_token/-1?url=%2Fspecialisation%2Fneurology%2Fean2020%2Fepilepsy%2Fprevalence-of-autoantibodies-in-epilepsy-almost-10%2F&agent=CCBot%2F2.0+%28https%3A%2F%2Fcommoncrawl.org%2Ffaq%2F%29&name=dev.mc.sense-studios.com&ip=3.93.74.25&categories=Conference+Report+Article%7CEpilepsy%7CNeurology%7CEAN+2020): failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 114

Notice: Trying to get property 'status' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 117

Notice: Trying to get property 'access_type' of non-object in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/header-tokenaccess.php on line 123
Prevalence of autoantibodies in epilepsy almost 10% - Medical Conferences

Home > Neurology > EAN 2020 > Epilepsy > Prevalence of autoantibodies in epilepsy almost 10%

Prevalence of autoantibodies in epilepsy almost 10%

Presented By
Dr Ronan McGinty, University of Oxford, UK

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
EAN 2020
At clinics in the UK, 9.3% of epilepsy outpatients had potentially pathogenic autoantibodies. The proportion of antibody-positive patients was similar across patients with new-onset focal epilepsy, drug-resistant epilepsy, and seizure-free epilepsy.

The prevalence of autoantibodies among people with epilepsy is not clear; rates between 5-80% have previously been reported. By determining the prevalence of largely pathogenic antibodies in prospectively recruited outpatients with new-onset focal epilepsy, drug-resistant epilepsy, and seizure-free epilepsy, British researchers aimed to provide a prevalence rate that is generalisable to the broader population of epilepsy patients [1]. They screened collected serum on live cell-based assays for neuronal-surface antibodies (NSAs) to LGI1, CASPR2, contactin-2, DPPX, antibodies to intracellular GAD65, and the GABAA, GABAB, glycine, and NMDA receptors. Overall, autoantibodies were detected in 51/546 (9.3%) epilepsy outpatients:

  • new-onset focal epilepsy, 24/232 (10.3%);

  • drug-resistant epilepsy, 22/260 (8.5%);

  • seizure-free epilepsy, 5/54 (9.3%);

  • healthy controls, 0/55 (0%).

New-onset focal epilepsy patients had NSAs only, whereas drug-resistant epilepsy and seizure-free epilepsy cohorts had NSAs and GAD65 antibodies (drug-resistant epilepsy: 11 NSAs, 11 GAD65; seizure-free epilepsy: 2 NSAs, 3 GAD65). In future studies, the pathophysiological role for antibodies in epilepsy should be examined. The authors concluded that the “striking” absence of GAD65 antibodies in new-onset focal epilepsy also warrants explanation.

 

  1. McGinty RN, et al. Abstract O3008, EAN 2020.

 



Posted on